DC
AXSM icon

Diametric Capital’s Axsome Therapeutics AXSM Stock Holding History

Diametric Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$599K Buy
+2,448
New +$531K 0.06% 304
2026
Q1 		– Sell
-1,525
Closed -$279K – 485
2025
Q4 		$279K Buy
+1,525
New +$213K 0.07% 310

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Diametric Capital's AXSM Position: Q2 2026 in Review

Diametric Capital opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 2,448 shares worth $599K. The stake represents 0.06% of the portfolio and ranks #304 among its holdings. This is a return to the name: Diametric Capital previously reported a position in AXSM as recently as Q4 2025.

Diametric Capital first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Diametric Capital held 2,448 shares of Axsome Therapeutics worth $599K as of Q2 2026.
  • Axsome Therapeutics was a new Diametric Capital position in Q2 2026.
  • Axsome Therapeutics made up 0.06% of Diametric Capital's portfolio in Q2 2026, its #304 holding.
  • Diametric Capital first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.